AI
Thursday, February 14, 2019 12:46:19 PM
CLSD RALLYYYYYYYYYYY and still trading massive below cash
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
